| --- | --- | --- | --- | --- | |-------|---------------------------------------|---------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | S e p t e m b e r 2 0 2 0 | | | | | | | | | | | Driving Value to Dermatology Partners | | | | | | | | | | | | | | | | | | | | | | Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. A ...

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q2 2020 Earnings Conference Call August 11, 2020 8:30 AM ET Company Participants Monique Kosse – LifeSci Advisors Dolev Rafaeli – President and Chief Executive Officer Matt Hill – Chief Financial Officer Conference Call Participants Suraj Kalia – Oppenheimer Jeffrey Cohen – Ladenburg Thalmann Shawn Boyd – Next Mark Capital Operator Greetings, and welcome to STRATA Skin SciencesÂ' Second Quarter 2020 Earnings Conference Call. [Operator Instructions] As a reminder, thi ...

Financial Data and Key Metrics Changes - For Q1 2020, the company's revenue was $6.7 million, a decrease of 10.1% compared to $7.5 million in Q1 2019, primarily due to the impact of COVID-19 on the overseas capital equipment business [28] - Recurring revenues increased by 7.3% to $5.7 million from $5.3 million in Q1 2019, driven by an increase in patient flow to partner clinics [28] - Gross profit for Q1 2020 was $4.4 million, representing 65.4% of revenues, compared to $4.6 million or 61.6% of revenues in Q1 2019 [29] - The net loss for Q1 2020 was $1 million, or $0.3 per share, compared to a net loss of $1.3 million, or $0.04 per share, in Q1 2019 [31] Business Line Data and Key Metrics Changes - Equipment revenue for Q1 2020 was down 52.6%, amounting to $1 million compared to $2.2 million in Q1 2019 [28] - The company experienced a growth in recurring revenue margins by 2.2% despite losing momentum in the last three weeks of March [25] Market Data and Key Metrics Changes - Up to mid-March 2020, reimbursement requests were up 117% compared to the same period in 2019, but dropped to approximately 50% of the same period in 2019 from mid-March to the end of April [11] - The company has reached out to over 350 physician partners across 31 states as part of its patient outreach program [18] Company Strategy and Development Direction - The company is focused on executing its strategy and planning for a return to normal operations while managing through the COVID-19 pandemic [9] - STRATA is leveraging its unique recurring revenue business model and resources to support partner clinics in rebuilding patient referrals [17] - The company is conducting online clinical training and webinars to engage with physician partners [22] Management's Comments on Operating Environment and Future Outlook - Management expressed that the pandemic has created significant uncertainties, but they believe they have sufficient funding to navigate the next four quarters [24] - The company anticipates that as states begin to reopen, there will be a pent-up demand for treatments, and they are preparing to support clinics in managing this demand [56] Other Important Information - As of March 31, 2020, the company had $15.6 million in cash and cash equivalents, with an additional $2 million received from the Paycheck Protection Program [32] - The company has implemented cash preservation measures, including employee leave of absence and reduced discretionary spending, expected to save approximately $3 million per quarter [23] Q&A Session Summary Question: How is the company evaluating accounts and physician partners during the pandemic? - The company is in contact with clinics to assess their operational status and patient volume, allowing them to identify the right targets for re-engagement [39] Question: Has there been increased interest from physicians based on AAD guidelines? - The company has seen significant participation in clinical webinars and communication from physicians regarding the guidelines, indicating heightened interest [47] Question: How is the company leveraging patient volumes from previous quarters? - The company has developed a patient outreach program to re-engage patients who were in treatment prior to COVID-19, utilizing their resources to assist clinics [49] Question: What is the company's outlook on cash preservation and top-line performance? - The company has projected a runway of four quarters based on current cash reserves and anticipated business recovery, with a focus on managing expenses [81]

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2019 Earnings Conference Call March 17, 2020 8:00 AM ET Company Participants Matt Picciano - LifeSci Advisors Dolev Rafaeli - President & Chief Executive Officer Matt Hill - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Joe Pantginis - H.C. Wainwright Suraj Kalia - Oppenheimer Shawn Boyd - Next Mark Capital Operator Greetings, and welcome to the STRATA Skin Sciences Fourth Quarter and Fiscal Year 2019 Earnings Call. At thi ...

Summary of STRATA Skin Sciences, Inc. Conference Call Company Overview - **Company**: STRATA Skin Sciences, Inc. (NASDAQ: SSKN) - **Date of Call**: October 30, 2019 - **Participants**: - Matthew Picciano - IR, LifeSci Advisors - Dolev Rafaeli - Chief Executive Officer - Matthew Hill - Chief Financial Officer Key Points Financial Performance - STRATA reported year-end 2018 financial results and is finalizing Q1-Q3 2019 results [7][8] - Revenue growth observed since 2018, particularly in recurring revenues [8] - Gross margins improved, with expectations for continued expansion [11][12] - 2018 revenue was $29.9 million, slightly lower than previously disclosed [26] - Net loss for 2018 was $4 million, an improvement from a net loss of $21.5 million in 2017 [28] Strategic Initiatives - Focus on direct-to-consumer (DTC) advertising has shown positive results, with a 29% increase in patients treated year-to-date compared to 2018 [10][11] - STRATA has successfully executed a turnaround strategy since 2018, including a $17 million financing and management changes [9][12] - The company has replaced approximately 100 nonperforming accounts and increased its installed base of XTRAC systems from 746 at the end of 2018 to 784 by Q3 2019 [13][27] Market Opportunities - STRATA is targeting private equity-owned dermatology clinics, having doubled its presence in this segment [13][40] - The company is expanding internationally, particularly in South Korea and Japan, with a focus on recurring revenue models [14][16][44] - The South Korean market is seen as a significant opportunity due to national health insurance reimbursement for treatments [44] Competitive Landscape - STRATA faces limited competition in the domestic market, with only one other direct competitor experiencing challenges [12][41] - The company is positioned as a gold standard in several international markets, including South Korea and Japan [16][43] Technological Advancements - STRATA launched the new XTRAC S3 308 nanometer laser, which offers improved treatment efficiency and user experience [18] - The company received 510(k) clearance for a multi-micro dose for the excimer laser, expected to enhance treatment outcomes [17] Risks and Challenges - The company has faced challenges related to tariffs and the complexities of international market entry [14][56] - Ongoing accounting restatements have been a distraction but are now resolved, allowing the company to refocus on growth [54] Future Outlook - STRATA plans to continue investing in DTC advertising and expanding its sales and marketing efforts [29][30] - The company aims to leverage its established presence in the U.S. while exploring growth opportunities in international markets [56] Additional Insights - STRATA has a strong cash position of over $16 million as of September 30, 2019, despite costs associated with the restatement process [29] - The company has approximately 100 employees, with 45 in field sales roles [50][51] - The total share count is approximately 32.9 million common shares outstanding [48] This summary encapsulates the key points discussed during the STRATA Skin Sciences conference call, highlighting the company's financial performance, strategic initiatives, market opportunities, competitive landscape, technological advancements, risks, and future outlook.